Cargando…

Effects of Fremanezumab on Medication Overuse in Japanese Chronic Migraine Patients: Post Hoc Analysis of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

INTRODUCTION: Chronic migraine (CM) patients commonly take acute headache medications, often resulting in medication overuse (MO). This post hoc analysis evaluated the efficacy of fremanezumab in CM patients from Japan with and without MO, which is not yet established. METHODS: A multicenter, double...

Descripción completa

Detalles Bibliográficos
Autores principales:	Imai, Noboru, Isogai, Yuki, Shibasaki, Yoshiyuki, Nakai, Masami, Ishida, Miki, Ning, Xiaoping, Koga, Nobuyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630291/ https://www.ncbi.nlm.nih.gov/pubmed/37695442 http://dx.doi.org/10.1007/s40120-023-00531-3

Ejemplares similares

Fremanezumab for Chronic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials
por: Saigoh, Kazumasa, et al.
Publicado: (2023)

Fremanezumab for Episodic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials
por: Saigoh, Kazumasa, et al.
Publicado: (2023)

Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b/3 trials in Japanese and Korean patients
por: Takeshima, Takao, et al.
Publicado: (2022)

Long-Term Safety and Tolerability of Fremanezumab for Migraine Preventive Treatment in Japanese Outpatients: A Multicenter, Randomized, Open-Label Study
por: Sakai, Fumihiko, et al.
Publicado: (2021)

Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients
por: Sakai, Fumihiko, et al.
Publicado: (2021)

Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients
por: Sakai, Fumihiko, et al.
Publicado: (2021)

Fremanezumab for migraine
Publicado: (2020)

The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study
por: Silberstein, Stephen D., et al.
Publicado: (2020)

Fremanezumab in the treatment of migraines: evidence to date
por: Robblee, Jennifer, et al.
Publicado: (2019)

Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials
por: Silberstein, Stephen D., et al.
Publicado: (2021)

Fremanezumab for Migraine Prevention in Japanese Elderly Aged Over 70 Years Old
por: Katsuki, Masahito, et al.
Publicado: (2023)

Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study
por: Lipton, Richard B., et al.
Publicado: (2020)

An Evidence-Based Review of Fremanezumab for the Treatment of Migraine
por: Urits, Ivan, et al.
Publicado: (2020)

Review of Tolerability of Fremanezumab for Episodic and Chronic Migraine
por: Root, Shane, et al.
Publicado: (2023)

Fremanezumab Improved Migraine and Headache Attributed to Glioblastoma
por: Kawamura, Shin, et al.
Publicado: (2022)

Fremanezumab for migraine prevention: more effective, less costly
Publicado: (2020)

One-Time Use of Galcanezumab or Fremanezumab for Migraine Prevention
por: Katsuki, Masahito, et al.
Publicado: (2023)

Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective study
por: Ohtani, Seiya, et al.
Publicado: (2023)

Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study
por: Goadsby, Peter J., et al.
Publicado: (2020)

Effect of fremanezumab on quality of life and productivity in patients with chronic migraine
por: Lipton, Richard B., et al.
Publicado: (2020)

Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial
por: Spierings, Egilius L. H., et al.
Publicado: (2021)

Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study
por: MaassenVanDenBrink, Antoinette, et al.
Publicado: (2021)

Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response
por: Pazdera, Ladislav, et al.
Publicado: (2021)

Fremanezumab for preventive treatment of migraine: Functional status on headache-free days
por: VanderPluym, Juliana, et al.
Publicado: (2018)

Population pharmacokinetic modelling and simulation of fremanezumab in healthy subjects and patients with migraine
por: Fiedler‐Kelly, Jill B., et al.
Publicado: (2019)

Fremanezumab: a disease-specific option for the preventive treatment of migraine, including difficult-to-treat migraine
por: Friedman, Deborah I., et al.
Publicado: (2020)

Fremanezumab in individuals with chronic migraine who had inadequate response to onabotulinumtoxinA and topiramate or valproic acid
por: Ferrari, Michel D., et al.
Publicado: (2022)

Lasmiditan in Japanese Patients with Common Migraine Comorbidities or Concomitant Medications: A Post Hoc Safety and Efficacy Analysis from the MONONOFU Study
por: Kitamura, Shigekazu, et al.
Publicado: (2023)

Effects of Fremanezumab on Psychiatric Comorbidities in Difficult-to-Treat Patients with Chronic Migraine: Post Hoc Analysis of a Prospective, Multicenter, Real-World Greek Registry
por: Vikelis, Michail, et al.
Publicado: (2023)

Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States
por: McAllister, Peter, et al.
Publicado: (2021)

Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies
por: Diener, Hans Christoph, et al.
Publicado: (2022)

Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies
por: McAllister, Peter, et al.
Publicado: (2022)

Predictors of Response to Fremanezumab in Migraine Patients with at Least Three Previous Preventive Failures: Post Hoc Analysis of a Prospective, Multicenter, Real-World Greek Registry
por: Argyriou, Andreas A., et al.
Publicado: (2023)

Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine
por: Ashina, Messoud, et al.
Publicado: (2021)

Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan
por: Suzuki, Shiho, et al.
Publicado: (2023)

Efficacy of Erenumab for Migraine Prevention in Japanese Patients with Episodic and Chronic Migraine: Results of a Post-Hoc Pooled Analysis
por: Kitamura, Shigekazu, et al.
Publicado: (2023)

Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
por: Driessen, Maurice T., et al.
Publicado: (2022)

Safety and Efficacy of Fremanezumab for the Prevention of Migraine: A Meta-Analysis From Randomized Controlled Trials
por: Gao, Bixi, et al.
Publicado: (2020)

COVID-19 pneumonia during long-term migraine prophylaxis with fremanezumab: a case report
por: Iannone, Luigi Francesco, et al.
Publicado: (2021)

Fremanezumab and Non-High-Dose Galcanezumab for Comorbid Cluster Headache in Patients with Migraine: Three Cases
por: Kashiwagi, Kenta, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qm3sv5ri65c4tg67iqmp95l450